| Janssen-Cilag AG - DARZALEX SC 1800 mg/15 ml, Injektionslösung |
| 67689 | | 01 | | DARZALEX SC 1800 mg/15 ml | | Injektionslösung | | L01FC01 | | | | 13.08.2020 | | |
|
| Composition |
| daratumumabum 1800 mg, hyaluronidasum humanum ADNr, histidinum, histidini hydrochloridum monohydricum, sorbitolum 735.1 mg, methioninum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 15 ml. |
| Packungsbestandteile |
| Solution injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Daratumumabum | 1800mg / 15ml |
| | BAG: Principe actif | Concentr. |
|---|
| Daratumumabum | 1800 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Histidin Hydrochloride Monohydrate | | | Histidine | | | Hyaluronidasum Humanum Adnr | | | Methionine | | | Polysorbatum 20 | | | Sorbitol | 735.1mg / 15ml |
| |
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | | 4788.48 | 5220.80 | A | LS | Oui |
|
